Antagonising angiogenesis in rheumatoid arthritis.
Brenchley
P E
PE
Department of Medicine, University of Manchester, UK. paul.brenchley@man.ac.uk
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D016228:Endothelial Growth Factors / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D005966:Glucuronidase / Q000378:metabolism; D006025:Glycosaminoglycans / Q000378:metabolism; D006133:Growth Substances / Q000378:metabolism*; D006497:Heparan Sulfate / Q000378:metabolism; D006801:Humans; D007596:Joints / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D008222:Lymphokines / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000517:prevention & control*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000099175:Heparanase
D020533:Angiogenesis Inhibitors; D016228:Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D005966:Glucuronidase; D006025:Glycosaminoglycans; D006133:Growth Substances; D006497:Heparan Sulfate; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000099175:Heparanase